Long-term effectiveness and safety of a nutraceutical based approach to reduce cholesterolemia in statin intolerant subjects with and without metabolic syndrome

Current Topics in Nutraceutical Research

Volumn 7, Issue 3-4, 2009, Pages 121-126

  Cicero, Arrigo F G ^a   Derosa, G ^b   Bove, M ^a   Imola, F ^a   Borghi, C ^a   Gaddi, A V ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Berberine; Hypercholesterolemia; Nutraceuticals; Phytosterols; Statin intolerance

Indexed keywords

ARMOLIPID PLUS; BERBERINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NUTRACEUTICAL; PRO ACTIV; UNCLASSIFIED DRUG; YOGHURT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; METABOLIC SYNDROME X; MYALGIA; PROSPECTIVE STUDY;

EID: 78649646382     PISSN: 15407535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Anfossi, G., Massucco, P., Bonomo, K. and Trovati, M. (2004) Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits. Nutrition Metabolism and Cardiovascular Disease 14, 215-224. (Pubitemid 39462927)
2. Caron, M.F. and White, C.M. (2001) Evaluation of the antihyperlipidemic properties of dietary supplements. Pharmacotherapy 21, 481-487. (Pubitemid 32275276)
3. Chen, J.T., Wesley, R. and Shamburek, R.D., Pucino, F. and Csako, G. (2005) Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. Pharmacotherapy 25, 171-183. (Pubitemid 40223479)
4. Cholesterol Treatment Trialists' (CTT) Collaborators. (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet 366, 1267-1278.
5. Cicero, A.F.G., Brancaleoni, M., Laghi, L., Donati, F. and Mino, M. (2005a) Antihyperlipidaemic effect of a Monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: a pilot study. Complementary Therapy in Medicine 13, 273-278. (Pubitemid 43032955)
6. Cicero, A.F.G., Derosa, G., Bove, M., Grandi, E., Uliassi, E., Borghi, C. and Gaddi, A.V. (2008) A nutraceutical based approach to reduce cholesterolemia in patients previously intolerant to more than a statin: a pilot study. Mediterranean Journal of Nutrition and Metabolism 1, 33-36.
7. Cicero, A.F.G., Derosa, G. and Gaddi, A. (2004) What herbalists suggest to our diabetic patients in order to improve their glycaemic control? Evaluation of scientific evidences and potential risks. Acta Diabetologica 41, 91-98. (Pubitemid 39304483)
8. Cicero, A.F.G., Gaddi, A.V. and Borghi, C. (2005b) Complementary medicine for hypertension: what evidence for herbalists suggestion? Evaluation of risks and potential applications. Evidence Based Integrative Medicine 2, 47-55.
9. Cicero, A.F.G., Linarello, S., Nascetti, S. and Gaddi, A.V. (2002) Scientific level evidence of suggestions given by 685 Italian herbalists for the dyslipidemias treatment. Nutrition Metabolism and Cardiovascular Disease 12, 237.
10. Cicero, A.F.G., Rovati, L. and Setnikar I. (2007) Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents in humans. Arzneimittelforschung 57, 26-30. (Pubitemid 46212985)
11. Daskalopoulou, S.S. and Mikhailidis, D.P. (2006) Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Current Medicine Research Opinion 22, 511-528.
12. Editors. (2008) In brief Zetia and Vytorin: the ENHANCE study. Medical Letter Drugs Therapy 50, 5.
13. European Diabetes Policy Group. (1999) A desktop guide to type 2 diabetes mellitus. Diabetic Medicine 16: 716-730
14. Kjekshus, J., Apetrei, E., Barrios, V., Böhm, M., Cleland, J.G., Cornel, J.H., Dunselman, P., Fonseca, C., Goudev, A., Grande, P., Gullestad, L., Hjalmarson, A., Hradec, J., Jánosi, A., Kamenský, G., Komajda, M., Korewicki, J., Kuusi, T., Mach, F., Mareev, V., McMurray, J.J., Ranjith, N., Schaufelberger, M., Vanhaecke, J., van Veldhuisen, D.J., Waagstein, F., Wedel, H. and Wikstrand J for the CORONA Group. (2007) Rosuvastatin in older patients with systolic heart failure. New England Journal of Medicine 357, 2248-2261. (Pubitemid 350190755)
15. Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., Pan, H., Wang, S., Wu, J., Wang, Y., Li, Z., Liu, J. and Jiang, J.D. (2004) Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nature Medicine 10, 1344-1351. (Pubitemid 40022716)
16. Lu, Z., Kou, W., Du, B., Wu, Y., Zhao, S., Brusco, O.A., Morgan, J.M. and Capuzzi, D.M.; Chinese Coronary Secondary Prevention Study Group. (2008) Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. American Journal of Cardiology 101, 1689-1693.
17. McKenney, J.M. (2006) An assessment of statin safety. American Journal of Managing Care 12, S310-317.
18. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). (2002). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143-3421.
19. Norman, G.R. and Streiner, D.L. (2000) Biostatistics The bare essential. 2nd ed. Canada: B.C. Decker Inc. Hamilton; 139-144.
20. Packard, C.J. (2004) Evolution of the HMG CoA Reductase Inhibitors (Statins) in Cardiovascular Medicine. British Journal of Cardiology 11(2), 129-136.
21. Poluzzi, E., Strahinja, P., Vaccheri, A., Vargiu, A., Silvani, M.C., Motola, D., Marchesini, G., De Ponti, F. and Montanaro, N. (2007) Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage. British Journal of Clinical Pharmacology 63(3), 346-355.
22. Prasad, G.V., Wong, T., Meliton, G. and Bhaloo, S. (2002) Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation 74, 1200-1201. (Pubitemid 35216122)
23. Smith, S.C. Jr., Allen, J., Blair, S.N., et al., AHA/ACC. (2006) National Heart, Lung and Blood Institute: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113, 2363-2372. (Pubitemid 43947981)
24. Thavendiranathan, P., Bagai, A., Brookhart, M.A. and Choudhry, N.K. (2006) Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Archives of Internal Medicine 166, 2307-2313. (Pubitemid 44833354)
25. Vladutiu, G.D., Simmons, Z., Isackson, P.J., Tarnopolsky, M., Peltier, W.L., Barboi, A.C., Sripathi, N., Wortmann, R.L. and Phillips, P.S. (2006) Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle and Nerve 34, 153-162. (Pubitemid 44167798)
26. Wanner, C. and Krane, V. (2006) Lessons learnt from the 4D trial. Nephrology Therapy 2, 3-7.
27. 2+ precipitation procedure for quantitation of high-densitylipoprotein cholesterol. Clinical Chemistry 28, 1379-1388.
28. Yin, J., Xing, H. and Ye, J. (2008) Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 57, 712-717. (Pubitemid 351608234)